LoginSignup
image de profil
capital_captain_2693
@capital_captain_2693
1Sem.·

Still looking for a share in the pharmaceutical sector?

Just tell us the title and preferably why you find it so interesting.

For your information $CAMX (-3,68 %) I already own


Many thanks in advance for all answers

1
32 Commentaires
image de profil
Dividendenopi👴@Dividendenopi
1Sem.
$NOVO B is currently on special offer 😉😇
•
18
•
image de profil
Tenbagger2024@Tenbagger2024
1Sem.
@Dividendenopi Software shares also
•
1
•
image de profil
lukaslr91@lukaslr91
1Sem.
@Dividendenopi NOVO has been on sale for more than a year and it is steadily...
••
image de profil
Dividendenopi👴@Dividendenopi
1Sem.
@Tenbagger2024 I'm really thinking about whether I should do without dividends for a bit 🤷‍♂️🤔🤔 and look for a few entry points
••
image de profil
Tenbagger2024@Tenbagger2024
1Sem.
@Dividendenopi
Good question, which software will survive? AI is already changing things
•
1
•
image de profil
Dividendenopi👴@Dividendenopi
1Sem.
@Tenbagger2024 That is a valid objection. We certainly need to reassess some companies. However, AI also brings advantages that are not yet so obvious. Let's run through the current reporting quarter and then sweep up the broken pieces and see what happens next
•
1
•
image de profil
Tenbagger2024@Tenbagger2024
1Sem.
@Dividendenopi
Because uncertainty about software will remain on the market.
•
1
•
image de profil
Dividendenopi👴@Dividendenopi
1Sem.
@Tenbagger2024 that's the way it is, it could have been different 🤷‍♂️
•
1
•
image de profil
Tenbagger2024@Tenbagger2024
1Sem.
@Dividendenopi
Not good for the project right now either 😭
•
1
•
image de profil
Dividendenopi👴@Dividendenopi
1Sem.
@Tenbagger2024 jo mei sogt da Bayer. 🙃 You sound a bit pissed off, but you should be above such days.
•
2
•
image de profil
Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin
1Sem.
@Dividendenopi lost too much weight too quickly.🤣 Fortunately, the yo-yo effect will probably not happen here.🤷🏼‍♂️
••
Voir toutes les 11 autres réponses
image de profil
Smudo@Smudeo
1Sem.
•
2
•
image de profil
Valesthor@Valesthor
1Sem.
$AZN is very broadly positioned in oncology incl. other things listed on the NYSE since yesterday looks very robust good growth.

$HIMS currently has problems with America as generics are being put on hold there to help large companies like Elli Lilly. But is very broadly positioned in telemedicine and online pharmacies. Probably has the greatest growth opportunities but also more risk AstraZeneca is more stable.
•
1
•
investment_wizard_2286@investment_wizard_2286
1Sem.
$RVMD is strong in oncology. 2 billion in cash available plus additional funds from a partnership.
Unfortunately I got out before the rocket ignited
•
1
•
Rookie@Rookie
1Sem.
$UCB Specialized in neurological diseases.
•
1
•
image de profil
Florian Simon@FloFinance
1Sem.
$ABBV has an exciting range of drugs in the fields of immunology and oncology, among others. I estimate that the Group will continue to grow diligently.
•
1
•
image de profil
Max@MaxlvomDach
1Sem.
•
1
•
image de profil
core_code@core_code
1Sem.
$BNTX through a large oncology pipeline and cash reserves of around EUR 17 billion to finance it
••
image de profil
alphawolf@alphawolf
1Sem.
$OMDA could really take off in the coming years thanks to its digitalization and customer growth
••
image de profil
Olli@Olli68
1Sem.
My favorite for this year is $SDZ 🚀 🚀 🚀
••
image de profil
PewPewPew@PewPewPew
1Sem.
$SDZ the generic market is about to boom
••
Participez à la conversation
S'inscrireConnexion